Pegipanermin - INmune Bio
Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTMLatest Information Update: 16 May 2025
At a glance
- Originator Emory University; Xencor
- Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
- Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
- Preclinical HER2 positive breast cancer
- No development reported Neurodegenerative disorders; Non-alcoholic steatohepatitis; Solid tumours
- Discontinued COVID-19 respiratory infection; Parkinson's disease
Most Recent Events
- 08 May 2025 INmune Bio plans a phase II trial for Major depressive disorder (Treatment-resistant) once NIH funding is available
- 30 Sep 2024 INmune Bio completes enrolment in its phase II trial for Alzheimer's disease (In the elderly) in US, Germany, Poland, the Czech Republic, Slovakia, Australia, United Kingdom, Spain, France, and Canada (NCT05318976)
- 24 Sep 2024 Efficacy data from the phase II trial in Alzheimer's disease released by INmune Bio